ºù«Ӱҵ

All publications

Journal articles

• Berdyshev E, Goleva E, Bronova I, Danby S, Bronoff A-S, Richers B, Boguniewicz M, Ramirez-Gama M, Garcia S, Zahn J , Agueusop I et al (2025) . Journal of Allergy and Clinical Immunology, 155(2), AB203-AB203.
• Irvine A, Paller A, Siegfried E, Cork M, Beck L, Chen Z, Peralta C, Zhang A, Levy S & Cyr S (2025) . Journal of Allergy and Clinical Immunology, 155(2), AB208-AB208.
• Alshiyab D, Ba-Shammakh SA, Al-Fakih A, Tashman O, Sarakbi D, Al-Qarqaz F, Muhaidat J, Atwan A & Cork MJ (2024) . J Dermatolog Treat, 35(1), 2296851.
• Berdyshev E, Thenie C, Goleva E, Danby S, Bronoff AS, Agueusop I, Zahn J, Gloaguen E, Bissonette R, Boguniewicz M , Ong P et al (2024) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 4(8), A205-A206.
• Skowron F, Pezzolo E, Cork MJ, Beecker J, Rodriguez A, Bennike N, Festini T, Ivens U & Tha?i D (2024) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 4(8), A370-A371.
• Guttman-Yassky E, Esfandiari E, Mano H, Arai T, Irvine AD, Cork MJ, Kabashima K, Chong C & Simpson E (2024) . Archives of Dermatological Research, 316(10).
• Geng B, Simpson E, Gooderham M, Gupta M, Deleuran M, Cork M, Biswas P & Koppensteiner H (2024) . Annals of Allergy, Asthma & Immunology, 133(6), S100-S100.
• Go R, Siegfried E, Cork M, Swanson E, Chen Z, Simcox E & Prescilla R (2024) . Annals of Allergy, Asthma & Immunology, 133(6), S96-S97.
• Sach TH, Williams HC, Allen H, Boyle R, Kelleher M, Brown S, Cork M, Flohr C, Jay N, Lartey S , Davies C et al (2024) . Value in Health, S1098-3015(24)02861.
• Paller AS, Silverberg JI, Simpson EL, Cork MJ, Arkwright PD, Chen Z, Bansal A, Prescilla R, Wang Z & Marco AR (2024) . Journal of the American Academy of Dermatology, S0190-9622(24)02896.
• Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, Cork MJ, Danby SG, Eichenfield L, Eyerich K , Gooderham M et al (2024) . British Journal of Dermatology, ljae342.
• Siegfried EC, Simpson EL, Cork MJ, Saeki H, Chen Z, Simcox E & Prescilla R (2024) . Journal of the American Academy of Dermatology, 91(3), AB189-AB189.
• Danby S, Andrew P, Brown K, Chittock J, Pinnock A, Williams S & Cork M (2024) . Journal of the American Academy of Dermatology, 91(3), AB259-AB259.
• Cork MJ, Ong P, Danby SG, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Bologna G, Zhang A & Leung DYM (2024) . Journal of the American Academy of Dermatology, 91(3), AB34-AB34.
• Cork MJ, Berdyshev E, Goleva E, Danby SG, Bronova I, Zahn J, Agueusop I, Bafna S, Ong P, Zhang A & Leung DYM (2024) . Journal of the American Academy of Dermatology, 91(3), AB34-AB34.
• Paller A, Geng B, Irvine A, Siegfried E, Cork M, Ramien M, Eichenfield L, Gupta R, Adams B, Ardeleanu M & Zhang A (2024) . Journal of the American Academy of Dermatology, 91(3), AB1-AB1.
• Ng SP, Bielfeldt S, Laing S, Danby S & Cork MJJ (2024) . Skin Pharmacology and Physiology, 1-10.
• Berdyshev E, Goleva E, Danby S, Bronoff A, Agueusop I, Zahn J, Gloaguen E, Bissonnette R, Boguniewicz M, Ong P , Zhang A et al (2024) . Journal of Investigative Dermatology, 144(8), S48-S48.
• Kosloski MP, Guttman©\Yassky E, Cork MJ, Worm M, Nahm D, Zhu X, Ruddy MK, Harel S, Kamal MA, Goulaouic H , Xu CR et al (2024) . Clinical and Translational Science, 17(8).
• Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B , Cork MJ et al (2024) . British Journal of Dermatology, ljae287.
• Bruce G, Rosala-Hallas A, Jones AP, Turner C, Dalton N, Hilger E, Baron S, Beattie P, Browne F, Brown SJ , Gach JE et al (2024) . British Journal of Dermatology, ljae276.
• Gribaleva E, Moreno CC, Malek R, Prieto-Merino D, Coker B, de la Cruz L, Baden M, Beattie P, Brown S, Burton T , Cameron S et al (2024) . British Journal of Dermatology, 191(Supplement_1), i55-i56.
• Carroll R, Gribaleva E, Malek R, Prieto-Merino D, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B , Cork MJ et al (2024) . British Journal of Dermatology, 191(Supplement_1), i61-i62.
• Cork MJ, Leung D, Ong P, Danby S, Ramirez-Gama M, Garcia S, Patricia T, Byers R, Matcher S, Zahn J , Bologna G et al (2024) . British Journal of Dermatology, 191(Supplement_1), i30-i30.
• Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B , Cork MJ et al (2024) . British Journal of Dermatology, 191(Supplement_1), i2-i3.
• Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH, Khokhar FA, Xiao J, Dubost-Brama A & Bansal A (2024) . American Journal of Clinical Dermatology, 25(4), 655-668.
• Cr¨¦py MN, Siegfried EC, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Khokhar FA, Bansal A, Prescilla R, Sierka D & Cyr SL (2024) . Revue Fran?aise d'Allergologie, 64, 104044-104044.
• Paller A, Cork M, Hong C-H, Soong W, Schneider S, Lo H, Pedersen LRM, Vacko E & Wollenberg A (2024) . British Journal of Dermatology, 190(Supplement_2), ii47-ii48.
• Bronova I, Berdyshev E, Goleva E, Danby S, Bronoff AS, Richers B, Garcia S, Gama MR, Taylor P, Zahn J , Agueusop I et al (2024) . Journal of Allergy and Clinical Immunology, 153(2), AB5-AB5.
• Burnett R, Cork M, Fann N, Chen H & Weichenthal S (2024) . Air Quality, Atmosphere & Health, 17(6), 1295-1305.
• Khemis A, Simpson E, Wollenberg A, Bewley A, Cork MJ, Hong CH, Soong W, Almgren P, Gjerum L, Carlsson A , Paller AS et al (2023) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 3(8), A363-A364.
• Chittock J, Kay L, Brown K, Cooke A, Lavender T, Cork MJ & Danby SG (2023) . Journal of Allergy and Clinical Immunology.
• Cork MJ, Tha?i D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, Kosloski MP, Dubost-Brama A, Prescilla R, Bansal A & Levit NA (2023) . Dermatology and Therapy, 13, 2697-2719.
• Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F, Brown SJ, Gach JE, Greenblatt D, Hearn R , Hilger E et al (2023) . British Journal of Dermatology, ljad281.
• Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan R, Bangert C, Beck L, Bieber T, Bernstein JA, Bertolin Colilla M , Berardi A et al (2023) . Clinical and Translational Allergy, 13(9).
• Sach TH, Lartey ST, Davies C, Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ , Lawton S et al (2023) . Clinical & Experimental Allergy.
• Siegfried EC, Simpson EL, Cork MJ, Arkwright PD, Wine Lee L, Chen Z, Prescilla R, Bansal A, Levit NA & Rodr¨ªguez Marco A (2023) . Dermatology and Therapy, 13(9), 1987-2000.
• Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O¡¯Malley JT & Porter-Brown B (2023) . British Journal of Dermatology, 189(5), 531-539.
• Duan MQ, Byers RA, Danby SG, Sahib S, Cha A, Zang C, Werth J, Adiri R, Taylor RN, Cork MJ & Matcher SJ (2023) . Biomedical Optics Express, 14(8), 4126-4126.
• Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC-H, Imafuku S, Schuttelaar MLA, Simpson EL, Soong W , Arlert P et al (2023) . JAMA Dermatology, 159(6), 596-596.
• Siegfried EC, Cork MJ, Katoh N, Zhang H, Chuang C-C, Thomas RB, Rossi AB, Cyr SL & Zhang A (2023) . American Journal of Clinical Dermatology, 24(5), 787-798.
• Winder N, Ashraf Z, Gohar S, Baalbaki N, Cork M, Danby S & Muthana M (2023) . Frontiers in Virology, 3.
• Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Tha?i D, de Bruin-Weller M, Weidinger S, Chan G, DiBonaventura M, Biswas P , Feeney C et al (2023) . American Journal of Clinical Dermatology, 24, 609-621.
• Flohr C, Irvine AD, Cork MJ, Simpson EL, Wollenberg A, Deleuran M, Praestgaard A, Thomas RB & Rossi AB (2023) . British Journal of Dermatology, 189(2), 238-240.
• Flohr C, Cork MJ, Ardern-Jones MR, Eichenfield LF, Barbarot S, Feeney C, Rojo R, Lazariciu I & Nesnas J (2023) . Journal of Dermatological Treatment, 34(1).
• Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen Y-F, Sun L, Schloebe A, Riedl E & Cork MJ (2023) . Clinical and Experimental Dermatology, 48(8), 881-888.
• Siegfried EC, Cork MJ, Boguniewicz M, Deleuran M, Simpson EL, Rossi A, Chen Z, Clearfield D, Shah P & Marco AR (2023) . Revue Fran?aise d'Allergologie, 63(3), 103434-103434.
• Cork MJ, Wollenberg A, Siegfried EC, Rossi AB, Chen Z, Levit NA & Marco AR (2023) . Revue Fran?aise d'Allergologie, 63(3), 103436-103436.
• Zuberbier T, Beck LA, Bedbrook A, de Bruin©\Weller M, Bousquet J, Cork M, Douladiris N, Katoh N, Mortz CG, Werfel T , Wojciech F et al (2023) . Clinical and Translational Allergy, 13(3).
• van den Bogaard EH, Elias PM, Goleva E, Berdyshev E, Smits JPH, Danby SG, Cork M & Leung DYM (2023) . The Journal of Allergy and Clinical Immunology: In Practice.
• Schachner L, Alexis A, Andriessen A, Baldwin H, Cork M, Kirsner R & Woolery-Lloyd H (2023) Supplement Individual Article: The Importance of a Healthy Skin Barrier From the Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A Review and Consensus. Journal of drugs in dermatology : JDD, 22(2), s3-SF344607s.
• Siegfried E, Cork M, Boguniewicz M, Deleuran M, Simpson E, Chen Z, Clearfield D, Shah P & Rodriguez-Marco A (2023) . Journal of Allergy and Clinical Immunology, 151(2), AB149-AB149.
• Schachner LA, Alexis AF, Andriessen A, Baldwin H, Cork MJ, Kirsner RS & Woolery-Lloyd H (2023) . JOURNAL OF DRUGS IN DERMATOLOGY, 22(2), S3-S14.
• Paller AS, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Gonzalez ME, Lockshin B, Chen Z, Bansal A, Levit NA & Prescilla R (2023) . Pediatric Drugs, 25, 67-77.
• Chittock J, Cork MJ & Danby SG (2022) . Journal of Investigative Dermatology.
• Thyssen JP, Silverberg J, Cork MJ, Taieb A, Malhotra BK, Johnson SL, Fostvedt L, Feeney C & Biswas P (2022) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 2(8), A342-A343.
• Simpson E, Silverberg J, Zdybski J, Cork MJ, Paul C, Feeney C, Clibborn C, Dibonaventura M, Biswas P & Guler E (2022) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 2(8), A335-A336.
• Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, Lawton S, Sach TH, Chalmers JR, Ridd MJ , Flohr C et al (2022) . Allergy.
• Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R , Lockshin B et al (2022) . The Lancet, 400(10356), 908-919.
• Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z , Kosloski MP et al (2022) . American Journal of Clinical Dermatology, 23(3), 365-383.
• Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD & Rossi AB (2022) . JID Innovations.
• Cork MJ, Guttman-Yassky E, Simpson EL, Soong W, Wang Z, Chuang CC, O¡¯malley JT & Bansal A (2022) . Revue Fran?aise d'Allergologie et d'Immunologie Clinique, 62(3), 321.
• Katibi OS, Cork MJ, Flohr C & Danby SG (2022) . Annals of Allergy, Asthma & Immunology.
• Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A, Ulhaq I, Fasth A, Carlander K, Holm T & Cork MJ (2022) . Clinical and Experimental Dermatology.
• Danby SG, Andrew PV, Kay LJ, Pinnock A, Chittock J, Brown K, Williams SF & Cork MJ (2021) . British Journal of Dermatology.
• Bewley A, Pontoppidan Thyssen J, Sin Chiu W, Rojo R, Biswas P, Feeney C, Dibonaventura M, Misery L, Staender S & Cork MJ (2021) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 1(8), A345-A346.
• Cork MJ, Eichenfield L, Flohr C, Bangert C, Barbarot S, Chan GL, Rojo R, Zhang F, Feeney C & Valdez H (2021) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 1(8), A354-A355.
• Flohr C, Cork MJ, Ardern Jones MR, Barbarot S, Feeney C, Rojo R, Biswas P & Nesnas J (2021) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie - FMC, 1(8), A348-A348.
• Zuberbier T, D?rr T, Aberer W, Alvaro M, Angier E, Arasi S, Arshad H, Ballmer©\Weber B, Bartra J, Beck L , B¨¦gin P et al (2021) . Allergy.
• Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, Zhang F, Myers DE & DiBonaventura M (2021) . Journal of the European Academy of Dermatology and Venereology.
• Paller A, Beck L, Blauvelt A, Cork M, Wollenberg A, Chen Z, Bates L, Cyr S & Zhang A (2021) . Annals of Allergy, Asthma & Immunology, 127(5), S16-S17.
• Simpson E, Cork M, Arkwright P, Deleuran M, Chen Z, Rodriguez Marco A, Cyr S & Harel S (2021) . Annals of Allergy, Asthma & Immunology, 127(5), S54-S55.
• Thyssen J, Silverberg J, Cork M, Taieb A, Malhotra B, Johnson S, Fostvedt L, Feeney C & Biswas P (2021) . Annals of Allergy, Asthma & Immunology, 127(5), S53-S54.
• Simpson EL, Paller AS, Siegfried EC, Tha?i D, Wollenberg A, Cork MJ, Marcoux D, Huang R, Chen Z, Rossi AB , Shumel B et al (2021) . Dermatology and Therapy, 11, 1643-1656.
• Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B , Hultsch T et al (2021) . Dermatitis, 32(1S), S81-S91.
• Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C & Cork MJ (2021) . Allergy and Asthma Proceedings, 42(5), 425-431.
• Paller AS, Wollenberg A, Siegfried E, Tha?i D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O¡¯Malley JT, Khokhar FA , Vakil J et al (2021) . Pediatric Drugs, 23(5), 515-527.
• Lin WC, Byers RA, Li W, Danby SG, Cork MJ & Matcher SJ (2021) . Biomedical Optics Express, 12(6), 3296-3311.
• Paller A, Cork MJ, Marcoux D, Zhang H, Chuang C, Zhang A & Chao J (2021) . Journal of Investigative Dermatology, 141(5), s84.
• O¡¯Kane D, Davis L, Ardern-Jones M, Laws P, Shaw L, Cork M, Velangi S, Cooper HL, Hudson R, Smith AB & Rout R (2021) Treatment outcomes of patients with atopic dermatitis (AD) treated with dupilumab through the early access to medicines scheme (EAMS) in the UK. Ulster Medical Journal, 90(2), 70-76.
• Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Klimek L, Bangert C, Barbarot S, Bieber T, de Bruin-Weller MS , Chernyshov PV et al (2021) . Journal of the European Academy of Dermatology and Venereology.
• Stamatas GN, Bensaci J, Greugny E, Kaur S, Wang H, Dizon MV, Cork MJ, Friedman AJ & Oddos T (2021) . Journal of Investigative Dermatology.
• Thyssen JP, Vestergaard C, Barbarot S, de Bruin©\Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C , Weidinger S et al (2021) . Journal of the European Academy of Dermatology and Venereology.
• Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G , Graham NMH et al (2021) . Journal of the European Academy of Dermatology and Venereology, 35(2), 464-475.
• Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Cork M (2021) . Journal of Allergy and Clinical Immunology, 147(2), AB28-AB28.
• McMichael A, Cork M, Teng J, Rojo R, Valdez H, Zhang F, Myers D, Chan G & DiBonaventura M (2021) . Journal of Allergy and Clinical Immunology, 147(2), ab156.
• Abuabara K, Nicholls SG, Langan SM, Guttman-Yassky E, Reynolds NJ, Paller AS, Brown SJ, Agner T, Aoki V, Bagot M , Barbarot S et al (2021) . British Journal of Dermatology.
• Cork MJ, Lockshin B, Morren M-A, Etoh T, Chen Z, Rossi AB, Lu Y, Bansal A & Shabbir A (2020) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie, 147(12), A362-A362.
• Danby SG, Andrew P, Kay L, Pinnock A, Brown K & Cork MJ (2020) . Journal of the American Academy of Dermatology, 83(6), AB71-AB71.
• Cork MJ, Lockshin B, Morren M-A, Etoh T, Chen Z, Rossi AB, Lu Y, Bansal A & Shabbir A (2020) . Journal of the American Academy of Dermatology, 83(6), AB39-AB39.
• Wollenberg A, Christen©\Z?ch S, Taieb A, Paul C, Thyssen JP, Bruin©\Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ , Kunz B et al (2020) . Journal of the European Academy of Dermatology and Venereology.
• Blaiss M, Cork M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Spergel J (2020) . Annals of Allergy, Asthma & Immunology, 125(5), S40-S41.
• Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Cork M (2020) . Annals of Allergy, Asthma & Immunology, 125(5), S46-S46.
• Wollenberg A, Blauvelt A, Guttman©\Yassky E, Worm M, Lynde C, Lacour J, Spelman L, Katoh N, Saeki H, Poulin Y , Lesiak A et al (2020) . British Journal of Dermatology.
• Cork MJ, Tha?i D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP , Kamal MA et al (2020) . British Journal of Dermatology.
• Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C , Magnolo N et al (2020) . The Lancet, 396(10246), 255-266.
• Danby SG, Draelos ZD, Gold LFS, Cha A, Vlahos B, Aikman L, Sanders P, Wu-Linhares D & Cork MJ (2020) . Journal of Dermatological Treatment.
• Danby SG, Andrew PV, Brown K, Chittock J, Kay LJ & Cork MJ (2020) . Dermatology and Therapy.
• Paller AS, Siegfried EC, Tha?i D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L , Weisman J et al (2020) . Journal of the American Academy of Dermatology.
• de Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C, Eckert L, Gadkari A & B¨¦go-Le Bagousse G (2020) . Journal of the American Academy of Dermatology.
• Wollenberg A, Flohr C, Simon D, Cork MJ, Thyssen JP, Bieber T, de Bruin-Weller MS, Weidinger S, Deleuran M, Taieb A , Paul C et al (2020) . Journal of the European Academy of Dermatology and Venereology.
• Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ, Lawton S, Simpson EL, Cork MJ , Sach TH et al (2020) . The Lancet, 395(10228), 962-972.
• Carr AN, DeWitt T, Cork MJ, Eichenfield LF, F?lster©\Holst R, Hohl D, Lane AT, Paller A, Pickering L, Taieb A , Cui TY et al (2020) . Pediatric Dermatology, 37(1), 130-136.
• Cork MJ, Tha?i D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M , Ardeleanu M et al (2020) . British Journal of Dermatology, 182(1), e47-e47.
• Cork MJ, Tha?i D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M , Ardeleanu M et al (2020) . British Journal of Dermatology, 182(1), e30-e30.
• Simpson JK, Martinez©\Queipo M, Onoufriadis A, Tso S, Glass E, Liu L, Higashino T, Scott W, Tierney C, Simpson MA , Desomchoke R et al (2020) . British Journal of Dermatology, 182(3), 729-737.
• Jabbar-Lopez ZK, Gurung N, Greenblatt D, Briley A, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA, Kong HH , Segre JA et al (2019) . BMJ Open, 9(8).
• Vestergaard C, Wollenberg A, Barbarot S, Christen©\Zaech S, Deleuran M, Spuls P, Flohr C, Trzeciak M, von Kobyletzki L, Seneschal J , Paul C et al (2019) . Journal of the European Academy of Dermatology and Venereology, 33(9), 1644-1659.
• Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoka Y , Remitz A et al (2019) . Journal of Dermatological Treatment.
• Berth©\Jones J, Exton LS, Ladoyanni E, Mohd Mustapa MF, Tebbs VM, Yesudian PD, Levell NJ, McHenry PM, Leslie TA, Wakelin S , Hunasehally RYP et al (2019) . British Journal of Dermatology, 180(6), 1312-1338.
• Thyssen JP, Bruin©\Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, Drucker AM, Foelster©\Holst R, Hoffmann CT, Eyerich K , Taieb A et al (2019) . Journal of the European Academy of Dermatology and Venereology.
• Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ & Guttman©\Yassky E (2019) . Journal of the European Academy of Dermatology and Venereology, 33(5), 807-815.
• Akinlade B, Guttman©\Yassky E, de Bruin©\Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J , Bachert C et al (2019) . British Journal of Dermatology.
• McPherson T, Exton LS, Biswas S, Creamer D, Dziewulski P, Newell L, Tabor KL, Wali GN, Walker G, Walker R , Walker S et al (2019) . British Journal of Dermatology, 181(1), 37-54.
• Simpson EL, Reynolds NJ, Flohr C, Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E & Irvine AD (2018) . Journal of the American Academy of Dermatology, 79(2), e25-e26.
• Liu Q, Zhang Y, Danby SG, Cork M & Stamatas G (2018) . BioMed Research International, 2018.
• de Bruin-Weller M, Tha?i D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L , Hultsch T et al (2018) . British Journal of Dermatology, 178(5), e366-e366.
• de Bruin-Weller M, Tha?i D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L , Hultsch T et al (2018) . British Journal of Dermatology, 178(5), e385-e385.
• de Bruin-Weller M, Tha?i D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L , Hultsch T et al (2018) . British Journal of Dermatology, 178(5), 1083-1101.
• Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, Mohd Mustapa MF, Exton LS, McHenry PM, Leslie TA , Wakelin S et al (2018) . British Journal of Dermatology, 178(4), 839-853.
• Byers RA, Maiti R, Danby SG, Pang EJ, Mitchell B, Carr¨¦ MJ, Lewis R, Cork MJ & Matcher SJ (2018) . Biomedical Optics Express, 9(4), 2001-2001.
• Irvine AD, Jones AP, Beattie P, Baron S, Browne F, Ashoor F, O'Neill L, Rosala-Hallas A, Sach T, Spowart C , Taams L et al (2018) . British Journal of Dermatology, 179(6), 1297-1306.
• Danby SG, Brown K, Wigley A, Chittock J, Pyae P, Flohr C & Cork M (2018) . Journal of Investigative Dermatology, 138(1), 68-77.
• Tha?i D, Wollenberg A, Remitz A, Cork MJ, Bieber T, Beissert S, Chen Z, Gadkari A, Eckert L, Hultsch T & Ardeleanu M (2017) . Annales de Dermatologie et de V¨¦n¨¦r¨¦ologie, 144(12), S266-S267.
• De Bruin-Weller M, Gadkari A, Simpson E, Cork M, Puig L, Girolomoni G, Wollenberg A, Chen Z, Radin A, Shumel B , Ardeleanu M et al (2017) . Annals of Allergy, Asthma & Immunology, 119(5), S94-S95.
• Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, Setterfield JF, Yesudian PD, McHenry PM, Gibbon K , Buckley DA et al (2017) . British Journal of Dermatology, 177(5), 1170-1201.
• Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, Bieber T, Vestergaard C, Brown SJ, Cork MJ , Drucker AM et al (2017) . Journal of the American Academy of Dermatology, 77(4), 623-633.
• Cork MJ & Danby SG (2017) . British Journal of Dermatology, 177(3), 608-609.
• Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ, Sach TH , Bradshaw LE et al (2017) . Trials, 18(1), 343-343.
• Koh MJ-A, Giam YC, Liew HM, Foong AY-W, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM & Cork MJ (2017) . Dermatol Ther (Heidelb).
• Christodoulides P, Hirata Y, Dominguez-Huttinger E, Danby SG, Cork M, Williams HC, Aihara K & Tanaka R (2017) . Royal Society of London. Philosophical Transactions A. Mathematical, Physical and Engineering Sciences, 375(2096).
• Koh MJ-A, Giam YC, Liew HM, Foong AY-W, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM & Cork MJ (2017) . Dermatology and Therapy.
• Smith CH, Jabbar©\Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R , Nelson©\Piercy C et al (2017) . British Journal of Dermatology, 177(3), 628-636.
• Danby SG, Wigley A, Cork MJ & Cork MJ (2017) Biologic Treatments for Atopic Eczema: Anti IL-4 and IL-13 biologics. Exchange: National Eczema Society Members' Magazine(163), 11-18.
• Johnston GA, Exton LS, Mohd Mustapa MF, Slack JA, Coulson IH, English JSC, Bourke JF, McHenry PM, Gibbon K, Buckley DA , Leslie TA et al (2017) . British Journal of Dermatology, 176(2), 317-329.
• Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR, McHenry PM, Gibbon K, Buckley DA, Nasr I, Duarte Williamson CE , Swale VJ et al (2017) . British Journal of Dermatology, 176(1), 20-43.
• Mohd Mustapa MF, Exton LS, Bell HK, Ormerod AD, Hughes JR, Levell NJ, Smith CH, McHenry PM, Gibbon K, Buckley DA , Leslie TA et al (2017) . British Journal of Dermatology, 176(1), 44-51.
• Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP , Kingo K et al (2016) . New England Journal of Medicine, 375, 2335-2348.
• Albenali LH, Danby S, Moustafa M, Brown K, Chittock J, Shackley F & Cork MJ (2016) . Journal of Allergy and Clinical Immunology, 138(5), 1715-1719.e4.
• Danby SG, Chalmers J, Brown K, Williams HC & Cork MJ (2016) . British Journal of Dermatology, 175(5), 1011-1019.
• Chittock J, Cooke A, Lavender T, Brown K, Wigley A, Victor S, Cork MJ & Danby SG (2016) . British Journal of Dermatology, 175(4), 713-720.
• Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, Yesudian PD, McHenry PM, Gibbon K, Buckley DA , Nasr I et al (2016) . British Journal of Dermatology, 175(1), 23-44.
• Danby SG, Brown K, Higgs-Bayliss T, Chittock J, Albenali L & Cork M (2016) . Skin Pharmacology and Physiology, 29(3), 135-147.
• Blume-Peytavi U, Lavender T, Jenerowicz D, Ryumina I, Stalder J-F, Torrelo A & Cork MJ (2016) . Pediatric Dermatology, 33(3), 311-321.
• Cooke A, Cork M, Victor S, Campbell M, Danby S, Chittock J & Lavender T (2016) . Acta Dermato Venereologica, 96(3), 323-330.
• Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, Eigenmann P, F?lster-Holst R, Gelmetti C, Gollnick H , Hamelmann E et al (2015) . Pediatric Allergy and Immunology, 26(4), 306-315.
• Chittock J, Brown K, Cork M & Danby S (2015) . Acta Dermato Venereologica, 95(6), 653-658.
• Cowdell F, Jadotte JT, Ersser SJ, Danby SG, Walton S, Lawton S, Roberts A, Gardiner E, Ware F & Cork MJ (2014) . Cochrane Database of Systematic Reviews, 2014(12), 1-16.
• Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, Brown SJ, Chen Z, Chen Y & Williams HC (2014) . Alergologia Polska - Polish Journal of Allergology, 1(4), T33-T41.
• Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, Brown SJ, Chen Z, Chen Y & Williams HC (2014) . Journal of Allergy and Clinical Immunology, 134(4), 818-823.
• Danby SG, Chittock J, Brown K, Albenali LH & Cork MJ (2014) . Br J Dermatol, 170(4), 914-921.
• Cork MJ, Mason AR, Mason J, Dooley G & Hancock H (2013) Topical Treatments for Chronic Plaque Psoriasis. Journal of the American Academy of Dermatology(In Press).
• Mason A, Mason J, Cork M, Hancock H & Dooley G (2013) . JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 69(5), 799-807.
• Mason AR, Mason JM, Cork MJ, Hancock H & Dooley G (2013) . BRITISH JOURNAL OF DERMATOLOGY, 169(3), 519-527.
• Moncrieff G, Cork M, Lawton S, Kokiet S, Daly C & Clark C (2013) . Clinical and Experimental Dermatology, 38(3), 231-238.
• Mason AR, Mason J, Cork MJ, Dooley G & Hancock H (2013) . Cochrane Database Syst Rev..
• Danby SG & Cork MJ (2013) . Br J Dermatol, 168(2), 235-236.
• Lu Z, Boadi J, Danby S, Cork M & Matcher SJ (2013) . Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 8565.
• Mason JM, Carr J, Buckley C, Hewitt S, Berry P, Taylor J & Cork MJ (2013) . BMC Dermatol, 13, 7.
• Lavender T, Bedwell C, Roberts SA, Carter L-A, Hart A, Turner MA & Cork MJ (2013) . JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing.
• Danby SG, AlEnezi T, Sultan A, Lavender T, Chittock J, Brown K & Cork MJ (2013) . Pediatr Dermatol, 30(1), 42-50.
• Lavender T, Furber C, Campbell M, Victor S, Roberts I, Bedwell C & Cork MJ (2012) . BMC Pediatrics, 12.
• Tsoi LC, Spain SL, Barker JNWN, Trembath RC, Knight J, Ellinghaus E, Schreiber S, Stuart PE, Tejasvi T, Gudjonsson JE , Voorhees JJ et al (2012) . Nature Genetics.
• Furber C, Bedwell C, Campbell M, Cork M, Jones C, Rowland L & Lavender T (2012) . JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 41(6).
• Knight J, Spain SL, Capon F, Hayday A, Nestle FO, Clop A, Barker JN, Weale ME & Trembath RC (2012) . Human Molecular Genetics, 21(23), 5185-5192.
• Bieber T, Cork M & Reitamo S (2012) Atopic dermatitis: A candidate for disease-modifying strategy. Allergy: European Journal of Allergy and Clinical Immunology.
• Cork MJ (2011) . BRITISH JOURNAL OF DERMATOLOGY, 165(6), 1159-1160.
• Moustafa M, Holden CR, Athavale P, Cork MJ, Messenger AG & Gawkrodger DJ (2011) . CONTACT DERMATITIS, 65(4), 208-212.
• Lavender T, Furber C, Cork M, Campbell M & Victor S (2011) . Archives of Disease in Childhood - Fetal and Neonatal Edition, 96(Supplement 1), Fa43-Fa43.
• Cork MJ & Danby S (2011) . Br J Dermatol, 164(6), 1179-1180.
• Lavender T, Bedwell C, O'Brien E, Cork MJ, Turner M & Hart A (2011) . BMC PEDIATR, 11.
• Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K & Cork MJ (2011) . Br J Dermatol, 165(2), 329-334.
• Moustafa M, Holden CR, Athavale P, Cork MJ, Messenger AG & Gawkrodger DJ (2011) . Contact Dermatitis, 65(4), 208-212.
• Vasilopoulos Y, Sagoo GS, Cork MJ, Walters K & Tazi-Ahnini R (2011) . J Hum Genet, 56(6), 423-427.
• Bangert C, Strober BE, Cork M, Ortonne JP, Luger T, Bieber T, Ferguson A, Ecker RC, Kopp T, Weise-Riccardi S , Guettner A et al (2011) . DERMATOLOGY, 222(1), 36-48.
• Cooke A, Cork MJ, Danby S & Lavender T (2011) . British Journal of Midwifery, 19(6), 354-362.
• Vasilopoulos Y, Sharaf N, di Giovine F, Simon M, Cork MJ, Duff GW & Tazi-Ahnini R (2011) . J Dermatol Sci, 61(2), 131-133.
• Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2 , Strange A, Capon F, Spencer CCA, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C , Bergboer JGM et al (2010) . Nat Genet, 42(11), 985-990.
• Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R & Ward SJ (2009) . J Invest Dermatol, 129(8), 1892-1908.
• Cork MJ & Danby S (2009) . Br J Nurs, 18(14), 872-877.
• Blume-Peytavi U, Cork MJ, Faergemann J, Szczapa J, Vanaclocha F & Gelmetti C (2009) . J EUR ACAD DERMATOL, 23(7), 751-759.
• Lavender T, Bedwell C, Tsekiri-O'Brien E, Hart A, Turner M & Cork M (2009) A qualitative study exploring women's and health professionals' views of newborn bathing practices. Evidence Based Midwifery, 7(4), 112-121.
• Mason AR, Mason J, Cork M, Dooley G & Edwards G (2009) . COCHRANE DB SYST REV(2).
• Tazi-Ahnini R, McDonagh AJG, Wengraf DA, Lovewell TRJ, Vasilopoulos Y, Messenger AG, Cork MJ & Gawkrodger DJ (2008) . Br J Dermatol, 159(3), 591-596.
• Vasilopoulos Y, Walters K, Cork MJ, Duff GW, Sagoo GS & Tazi-Ahnini R (2008) . Eur J Hum Genet, 16(8), 1002-1009.
• Cork MJ, Varghese J, Sultan A, Guy R, Lane M, AlEnezi T, Hadgraft J & Ward SJ (2008) . Dermatitis, 19(4), 218-238.
• Simon M, Tazi-Ahnini R, Jonca N, Caubet C, Cork MJ & Serre G (2008) . Br J Dermatol, 159(1), 77-85.
• Wengraf DA, McDonagh AJG, Lovewell TRJ, Vasilopoulos Y, Macdonald-Hull SP, Cork MJ, Messenger AG & Tazi-Ahnini R (2008) . Tissue Antigens, 71(3), 206-212.
• Cork MJ, Danby S, Vasilopoulos Y, Moustafa M, MacGowan A, Varghese J, Duff GW, Tazi-Ahnini R & Ward SJ (2008) . Drug Discovery Today: Disease Mechanisms, 5(1).
• Vasilopoulos Y, Cork MJ, Teare D, Marinou I, Ward SJ, Duff GW & Tazi-Ahnini R (2007) . Allergy, 62(5), 514-519.
• Langley RGB, Luger TA, Cork MJ, Schneider D & Paul C (2007) . DERMATOLOGY, 215, 27-44.
• Kemp EH, McDonagh AJG, Wengraf DA, Messenger AG, Gawkrodger DJ, Cork MJ & Tazi-Ahnini R (2006) . Hum Immunol, 67(7), 535-539.
• Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ & Tazi-Ahnini R (2006) . J Allergy Clin Immunol, 118(1), 3-21.
• Carlisle J, Shickle D, Cork M & McDonagh A (2006) . J Med Ethics, 32(3), 133-137.
• Chen HM, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ , Rafie-Kolpin M et al (2006) . HUM MOL GENET, 15(4), 519-529.
• Mee JB, Cork MJ, di Giovine FS, Duff GW & Groves RW (2006) . Cytokine, 33(2), 72-78.
• Paul C, Cork M, Rossi AB, Papp KA, Barbier N & de Prost Y (2006) . PEDIATRICS, 117(1), E118-E128.
• Hengge UR, Ruzicka T, Schwartz RA & Cork MJ (2006) . J AM ACAD DERMATOL, 54(1), 1-15.
• Cork MJ, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, Mac Gowan A, Ward SJ & Tazi-Ahnini R (2005) Predisposition to sensitive skin and atopic eczema.. Community Pract, 78(12), 440-442.
• Stevens KJ, Brazier JE, McKenna SP, Doward LC & Cork MJ (2005) . Br J Dermatol, 153(2), 372-377.
• STRAUSS RM, FERGUSON AD, RITTEY CDC & CORK MJ (2005) . Pediatric Dermatology, 22(4), 373-374.
• Lench N, Iles MM, Mackay I, Patel R, Sagoo GS, Ward SJ, Dechairo B, Olavesen M, Carey A, Duff GW , Cork MJ et al (2005) . J Invest Dermatol, 124(3), 545-552.
• Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S , Paller A et al (2005) . DERMATOLOGY, 211(2), 77-78.
• Sagoo GS, Cork MJ, Patel R & Tazi-Ahnini R (2004) . J Dermatol Sci, 35(3), 171-179.
• Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW, Ward SJ & Tazi-Ahnini R (2004) . J Invest Dermatol, 123(1), 62-66.
• Bowling DJ & Cork DMJ (2003) . Journal of Dermatological Treatment, 14(3), 190-191.
• Cork MJ, Britton J, Butler L, Young S, Murphy R & Keohane SG (2003) . Br J Dermatol, 149(3), 582-589.
• Tazi-Ahnini R, Cork MJ, Wengraf D, Wilson AG, Gawkrodger DJ, Birch MP, Messenger AG & McDonagh AJG (2003) . Hum Genet, 112(4), 400-403.
• Goustas P, Cork MJ & Higson D (2003) Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety.. The Journal of dermatological treatment, 14(2), 71-85.
• Cork MJ, Timmins J, Holden C, Carr J, Berry V, Tazi-Ahnini R & Ward SJ (2003) An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharmaceutical Journal, 271(7277), 747-748.
• Tazi-Ahnini R, Cork MJ, Gawkrodger DJ, Birch MP, Wengraf D, McDonagh AJG & Messenger AG (2002) . Tissue Antigens, 60(6), 489-495.
• Tazi-Ahnini R, Cork MJ, Gawkrodger D, Wengraf D, Messenger AG & McDonagh AJG (2002) Role of the autoimmune regulator (AIRE) gene in alopecia areata: Strong association of a potentially functional AIRE polymorphism with alopecia universalis. J INVEST DERMATOL, 119(3), 719-719.
• Henderson JK, Taylor HR, Bavik CO, Ward SJ, Cork MJ & Tazi-Ahnini R (2002) Tumour necrosis factor-alpha induced up-regulation of elafin and antileukoprotease enhances the skin barrier. J INVEST DERMATOL, 119(3), 729-729.
• Chen M-H, Antoni L, Tazi-Ahnini R, Cork M, Ward SJ & B?vik CO (2002) . Mechanisms of Development, 114(1-2), 205-212.
• Mason J, Mason AR & Cork MJ (2002) Topical preparations for the treatment of psoriasis: a systematic review. BRIT J DERMATOL, 146(3), 351-364.
• Tazi-Ahnini R, Cox A, McDonagh AJG, Nicklin MJH, di Giovine FS, Timms JM, Messenger AG, Dimitropoulou P, Duff GW & Cork MJ (2002) . Eur J Immunogenet, 29(1), 25-30.
• Tazi-Ahnini R, McDonagh A, Cox A, di Giovine F, Messenger A, Duff G & Cork M (2001) Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL1-L1 in alopecia areata: Strong disease associations and possible gene interaction. J INVEST DERMATOL, 117(2), 431-431.
• Tazi-Ahnini R, McDonagh AJ, Cox A, Messenger AG, Britton JE, Ward SJ, B?vik CO, Duff GW & Cork MJ (2001) . Heredity (Edinb), 87(Pt 2), 215-219.
• Tazi-Ahnini R, di Giovine FS, McDonagh AJG, Messenger AG, Amadou C, Cox A, Duff GW & Cork MJ (2000) . Human Genetics, 106(6), 639-645.
• Tazi-Ahnini R, di Giovine FS, McDonagh AJ, Messenger AG, Amadou C, Cox A, Duff GW & Cork MJ (2000) . Hum Genet, 106(6), 639-645.
• Mason J, Mason AR & Cork MJ (2000) . British Journal of Dermatology, 142(3), 351-364.
• Ahnini RT, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW & Di Giovine FS (2000) Corrigendum: Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis (Human Molecular Genetics (2000) 8 (1135-1140)). Human Molecular Genetics, 9(4), 659.
• Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, Finlay AY, Wilson NJE, Graham-Brown RAC, Sowden JM , Beard AL et al (2000) Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. BRIT J DERMATOL, 142(1), 52-58.
• Tazi-Ahnini R, di Giovine FS, Cox A, Keohane SG & Cork MJ (1999) . Lancet, 354(9178), 597.
• Tazi Ahnini R, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW & di Giovine FS (1999) . Hum Mol Genet, 8(6), 1135-1140.
• Ahnini RT, Cork M, Camp N, Mee J, Keohane S, Duff G & di Giovine F (1999) Genetic association between MHC S gene and susceptibility to psoriasis. J INVEST DERMATOL, 112(4), 591-591.
• Carter MJ, di Giovine FS, Sorrell JA, Wilson AG, Keohane S, Cork MJ, Sanders DS, Duff GW & Lobo AJ (1999) Genetic susceptibility and disease behaviour in Crohns disease: The role of tumour necrosis factor alpha gene promoter polymorphisms. GUT, 44, A29-A29.
• Carter MJ, di Giovine FS, Sorrell JA, Wilson AG, Keohane S, Cork MJ, Sanders DS, Duff GW & Lobo AJ (1999) The tumor necrosis factor alpha gene promoter polymorphisms and Crohns disease: Study of genetic suscepibility and disease behavior. GASTROENTEROLOGY, 116(4), A678-A678.
• Cockayne SE, Cork MJ & Gawkrodger DJ (1999) Treatment of psoriasis: day care vs. inpatient therapy. BRIT J DERMATOL, 140(2), 375-376.
• Cork MJ (1999) Taking the itch out of eczema: How the careful use of emollients can break the itch-scratch cycle of atopic eczema. Asthma Journal, 4(3), 116-120.
• Kemp EH, Ajjan RA, Waterman EA, Gawkrodger DJ, Cork MJ, Watson PF & Weetman AP (1999) . Br J Dermatol, 140(1), 73-78.
• Humphrey KM, Cork MJ & Haycox A (1998) A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. BRIT J DERMATOL, 139(4), 660-664.
• Mee JB & Cork MJ (1998) Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J INVEST DERMATOL, 110(3), 301-302.
• Cork MJ (1997) The importance of skin barrier function. J DERMATOL TREAT, 8, S7-S13.
• Cork MJ, Keohane SG, Gawkrodger DJ, Hancock BW, Sheridan E & Bleehen SS (1997) Cytokine dermatosis: Reactivation of eczema during interleukin-2 infusion. BRIT J DERMATOL, 136(4), 644-645.
• Tarlow JK, Cork MJ, Clay FE, SchmittEgenolf M, Crane AM, Stierle C, Boehncke WH, Eiermann TH, Blakemore AIF, Bleehen SS , Sterry W et al (1997) Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. BRIT J DERMATOL, 136(1), 147-148.
• Cork MJ, Crane AM & Duff GW (1996) . Dermatol Clin, 14(4), 671-678.
• Clay FE, Cork MJ, Wilson AG, Crane AM, Lewis F, Harrington CI & Duff GW (1996) . Exp Dermatol, 5(4), 227-229.
• Cork MJ (1996) . Journal of the European Academy of Dermatology and Venereology, 7(S1).
• BerthJones J, Finlay AY, Zaki I, Tan B, Goodyear H, LewisJones S, Cork MJ, Bleehen SS, Salek MS, Allen BR , Friedmann P et al (1996) Cyclosporine in severe childhood atopic dermatitis: A multicenter study. J AM ACAD DERMATOL, 34(6), 1016-1021.
• Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ & Duff GW (1996) . Hum Genet, 97(6), 723-726.
• Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJH & Duff GW (1996) . Human Genetics, 97(6), 723-726.
• CORK MJ, DIGIOVINE FS, CRANE SA, MEE JB & DUFF GW (1995) NOVEL GENETIC ASSOCIATION OF AN IL-1-BETA GENE VARIATION AT-+3953, SUSCEPTIBILITY TO PSORIASIS AND IL-1-BETA PROTEIN-PRODUCTION. J INVEST DERMATOL, 105(3), 453-453.
• KEOHANE SG & CORK MJ (1995) TREATMENT OF GROVERS-DISEASE WITH CALCIPOTRIOL (DOVONEX(R)). BRIT J DERMATOL, 132(5), 832-833.
• Wilson AG, Clay FE, Crane AM, Cork MJ & Duff GW (1995) . J Invest Dermatol, 104(5), 856-858.
• Cork MJ, Tarlow JK, Clay FE, Crane A, Blakemore AI, McDonagh AJ, Messenger AG & Duff GW (1995) . J Invest Dermatol, 104(5 Suppl), 15S-16S.
• Clay FE, Cork MJ, Tarlow JK, Blakemore AI, Harrington CI, Lewis F & Duff GW (1994) . Hum Genet, 94(4), 407-410.
• CLAY FE, CORK MJ, TARLOW JK, BLAKEMORE AIF, LEWIS F, HARRINGTON CI & DUFF GW (1994) ASSOCIATION OF THE INTERLEUKIN ONE RECEPTOR ANTAGONIST GENE POLYMORPHISM WITH LICHEN-SCLEROSUS. J INVEST DERMATOL, 103(3), 408-408.
• Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P & Duff GW (1994) . Arthritis Rheum, 37(9), 1380-1385.
• Tarlow JK, Clay FE, Cork MJ, Blakemore AI, McDonagh AJ, Messenger AG & Duff GW (1994) . J Invest Dermatol, 103(3), 387-390.
• Lewis FM, Cork MJ, McDonagh AJ & Gawkrodger DJ (1994) . Contact Dermatitis, 30(4), 214-216.
• Cork MJ, Tarlow JK, Blakemore AI, Mee JB, Crane AM, Stierle C, Bleehen SS & Duff GW (1993) Psoriasis and interleukin-1. A translation.. J R Coll Physicians Lond, 27(4), 366.
• Cork MJ, Tarlow JK, Wilson AG, Blakemore AIF, Messer G, Kind P, Gordon C, Emery P, Bleehen SS & Duff GW (1993) . Journal of Dermatological Science, 6(1), 18-18.
• Mee JB, Cork MJ, di Giovine FS, Duff GW & Bleehen SS (1993) . Journal of Dermatological Science, 6(1), 2-2.
• CORK MJ, MEE JB, TARLOW JK, BLAKEMORE AIF, DIGIOVINE F, BLEEHEN SS & DUFF GW (1993) INTERLEUKIN ONE RECEPTOR ANTAGONIST POLYMORPHISM - ALLELIC ASSOCIATION WITH INFLAMMATORY DERMATOSES. J INVEST DERMATOL, 100(4), 448-448.
• CORK MJ, TARLOW JK, BLAKEMORE AIF, MCDONAGH AJG, MESSENGER AG, BLEEHEN SS & DUFF GW (1993) GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. J INVEST DERMATOL, 100(4), 522-522.
• CORK MJ, TARLOW JK, BLAKEMORE AIF, MCDONAGH AJG, MESSENGER AG, BLEEHEN SS & DUFF GW (1993) GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. CLIN RES, 41(2), A179-A179.
• Stainforth J, MacDonald-Hull S, Papworth-smith J, Eady E, Cunliffe W, Norris J, Simpson N & Cork M (1993) . Journal of Dermatological Treatment, 4(3), 119-122.
• Lewis FM, Cork MJ, McDonagh AJ & Gawkrodger DJ (1993) . Contact Dermatitis, 28(1), 40-41.
• Barradell R, Addo A, McDonagh AJ, Cork MJ & Wales JK (1993) . Eur J Pediatr, 152(4), 291-292.
• McDonagh AJ, Wright AL, Cork MJ & Gawkrodger DJ (1992) . Br J Dermatol, 126(1), 16-18.
• MCDONAGH AJG, CORK MJ & HARRINGTON CI (1991) PYODERMA-GANGRENOSUM. BRIT MED J, 303(6807), 925-925.
• Gawkrodger DJ, Cork MJ & Bleehen SS (1991) . Contact Dermatitis, 25(3), 200-201.
• Cork MJ, Cooke NJ & Mellor E (1990) . BMJ, 301(6765), 1398-1398.
• Cork MJ, Riches AC & Wright EG (1986) . British Journal of Haematology, 63(4), 775-783.
• Cork MJ, Wright EG & Riches AC (1982) . Leukemia Research, 6(4), 553-565.
• Thomas DB, Cork MJ & Riches AC (1981) The regulation of the haematopoietic stem cell compartment in foetal liver.. Progress in clinical and biological research, 59 B, 277-285.
• Cork M, Anderson I, Thomas DB & Riches A (1981) . Leukemia Research, 5(1), 101-105.
• Riches AC, Cork MJ & Thomas DB (1981) The control of haematopoietic stem cell proliferation by humoral factors.. Progress in clinical and biological research, 59 B, 269-276.
• Riches AC, Cork MJ & Thomas DB (1980) Changes in the growth fraction of haempoietic stem cells following treatment with normal rat bone marrow extract. Cell and Tissue Kinetics, 13(2), 211-212.
• Williams SF, Chittock J, Brown K, Kay LJ, Cork MJ & Danby SG () . Applied Spectroscopy.
• Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF, Khokhar FA, Coleman A, Gherardi G, Chen Z , Zhang A et al () . Pediatric Dermatology.
• Danby SG, Matcher S, Byers R, Taylor R, Sahib S, Andrew P, Brown K, Kay L, Wright C, Pinnock A , Chittock J et al () . JEADV Clinical Practice.
• Yeo TF, Labbouz S, Lawrance N, Sitaraaman HB, Tattersall RS & Cork MJ () . JEADV Clinical Practice.
• Gooderham MJ, de Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL, Tsianakas A, Kerkmann U, Feeney C & Romero W () . Dermatology and Therapy.
• Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, Sach TH, Lawton S, Flohr C, Ridd MJ , Chalmers JR et al () . Health Technology Assessment, 1-116.
• Paller A, Eichenfield L, Silverberg J, Cork M, Bangert C, Irvine A, Weidinger S, Barbarot S, Fan H, Alderfer J , Koppensteiner H et al () . SKIN The Journal of Cutaneous Medicine, 8(2), s379-s379.
• Wollenberg A, Cork M, Hong C-H, Kurbasic A, Vacko E & Paller A () . SKIN The Journal of Cutaneous Medicine, 8(2), s377-s377.
• Cork MJ, Lockshin B, Pinter A, Chen Z, Shumel B & Prescilla R () . Acta Dermato-Venereologica, 104, adv13467-adv13467.
• Cork M, Danby S, Rossi AB & Bansal A () . Drug Design, Development and Therapy, Volume 18, 277-289.
• Paller AS, Siegfried EC, Cork MJ, Arkwright PD, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL () . Pediatric Drugs.
• Paller A, Cork M, Flohr C, Bangert C, Weidinger S, Nesnas J, Farooqui S, Biswas P, Watkins M & Koppensteiner H () . SKIN The Journal of Cutaneous Medicine, 8(1), s329-s329.
• Paller A, Cork M, Hong C-H, Soong W, Schneider S, Lo H, Pedersen LRM, Vacko E & Wollenberg A () . SKIN The Journal of Cutaneous Medicine, 8(1), s323-s323.
• Andrew PV, Pinnock A, Poyner A, Brown K, Chittock J, Kay LJ, Cork MJ & Danby SG () . Dermatology and Therapy.
• Williams SF, Wan H, Chittock J, Brown K, Wigley A, Cork MJ & Danby SG () . Clinical and Experimental Dermatology.
• Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR & Wollenberg A () . American Journal of Clinical Dermatology.
• Wollenberg A, Cork M, Flohr C, Bewley A, Blauvelt A, Hong C-H, Imafuku S, Schuttelaar MLA, Simpson E, Soong W , Amoudruz P et al () . SKIN The Journal of Cutaneous Medicine, 7(2), s140-s140.
• Paller A, Silverberg J, Hong HCH, Cork M, Puig L, Arlert P, Kurbasic A, Soldbro L & Simpson E () . SKIN The Journal of Cutaneous Medicine, 7(2), s139-s139.
• Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, Kim MB, Kabashima K, Chen Z, Lu Y , Bansal A et al () . JAMA Dermatology.
• Paller AS, Silverberg JI, Hong C-H, Cork M, Puig L, Arlert P, Kurbasic A, Soldbro L & Simpson EL () . SKIN The Journal of Cutaneous Medicine, 6(6), s77-s77.
• Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KCL, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E , Shimojo N et al () . Cochrane Database of Systematic Reviews, 2022(11).
• McPherson T, Cork MJ, Goodhead C, Michaelis LJ, Flohr C, Petrovic M, Hennessy L, Rajkovic I & Hudson R () . Pediatric Dermatology.
• Paller AS, Beck LA, Blauvelt A, Siegfried EC, Cork MJ, Wollenberg A, Chen Z, Khokhar FA, Vakil J, Zhang A , Bansal A et al () . Pediatric Dermatology.
• Kelleher MM, Cro S, Van Vogt E, Cornelius V, Lodrup Carlsen KC, Skjerven HO, Rehbinder EM, Lowe A, Dissanayake E, Shimojo N , Yonezawa K et al () . Clinical & Experimental Allergy.
• Kelleher MM, Cro S, Cornelius V, Lodrup Carlsen KC, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E, Shimojo N, Yonezawa K , Ohya Y et al () . Cochrane Database of Systematic Reviews.
• Blaiss M, Cork M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Spergel J () . SKIN The Journal of Cutaneous Medicine, 5(1), s12-s12.
• Silverberg J, Barbarot S, Gooderham M, Simon J, Simpson E, Kurbasic A, Olsen C & Cork M () . SKIN The Journal of Cutaneous Medicine, 5(1), s9-s9.
• Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Cork M () . SKIN The Journal of Cutaneous Medicine, 5(1), s13-s13.
• Jabbar©\Lopez ZK, Ung CY, Alexander H, Gurung N, Chalmers J, Danby S, Cork MJ, Peacock JL & Flohr C () . Clinical & Experimental Allergy.
• Silverberg JI, Cork M, Wollenberg A, Katoh N, Steffensen LA, Kurbasic A, Olsen CK, Kuznetsova A, ?sterdal ML, Vilsb?ll AW & Deleuran M () . SKIN The Journal of Cutaneous Medicine, 4(6), s98-s98.
• Cork M, Tha?i D, Eichenfield L, Arkwright P, Chen Z, Kamal M, O'Malley J & Bansal A () . SKIN The Journal of Cutaneous Medicine, 4(6), s104-s104.
• Thyssen JP, Vestergaard C, Deleuran M, Bruin©\Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C , Weidinger S et al () . Journal of the European Academy of Dermatology and Venereology.
• Kelleher MM, Cro S, Cornelius V, Axon E, Lodrup Carlsen KC, Skjerven HO, Rehbinder EM, Lowe A, Dissanayake E, Shimojo N , Yonezawa K et al () . Cochrane Database of Systematic Reviews.
• Cooke A, Victor S, Cork M & Lavender T () . Cochrane Database of Systematic Reviews.
• Cooke A, Victor S, Cork M & Lavender T () . Cochrane Database of Systematic Reviews.
• Cork MJ, Danby SG & Ogg GS () . Journal of Dermatological Treatment.
• Cork MJ, Tha?i D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M , Ardeleanu M et al () . British Journal of Dermatology.
• Danby SG, Andrew PV, Brown K, Chittock J, Kay LJ & Cork MJ () . Dermatology and Therapy.
• Jabbar©\Lopez ZK, Ezzamouri B, Briley A, Greenblatt D, Gurung N, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA , Danby S et al () . Clinical & Experimental Allergy.

Chapters

• Danby SG & Cork MJ (2018) , pH of the Skin: Issues and Challenges (pp. 95-107). S. Karger AG
• Danby S, Bedwell C & Cork MJ (2014) Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders
• Cork MJ & Danby SG (2012) Current and Future Trends: Skin Diseases and Treatment In Benson HAE & Watkinson AC (Ed.), Topical and Transdermal Drug Delivery Wiley
• Cork MJ & Danby S (2011) The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd..
• Cork MJ, Moustafa M, Danby S, Vasilopoulos Y, Tazi-Ahnini R, Ward SJ, Hadgraft J, Lane ME, Guy R & MacGowan A (2009) , Basic and Clinical Dermatology (pp. 211-240). Informa Healthcare
• Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane M, Moustafa M, Guy R, MacGowan A, Tazi-Ahnini R & Ward SJ (2009) Epidermal Barrier Dysfunction in Atopic Dermatitis In Rawlings L (Ed.), Skin Moisturization USA: Informa Healthcare USA Inc..

Conference proceedings papers

• Wollenberg A, Cork M, Chih-ho-Hong H, Kurbasic A, Vacko E & Paller AS (2024) Progressive and sustained Disease Control in Patients with atopic Dermatitis (AD) aged 12 to 17 Years treated with Tralokinumab for 52 Weeks. ALLERGOLOGIE, Vol. 47(9)
• Wollenberg A, Paller AS, Bewley A, Cork M, Chih-ho-Hong H, Soong W, Oland CB, Gjerum L & Blauvelt A (2024) Langzeitwirksamkeit von Tralokinumab bei Jugendlichen mit mittelschwerer bis schwerer Atopischer Dermatitis. ALLERGOLOGIE, Vol. 47(9)
• Berdyshev E, Goleva E, Danby S, Bronoff A, Agueusop I, Zahn J, Gloaguen E, Bissonnette R, Boguniewicz M, Ong P , Zhang A et al (2024) Children with atopic dermatitis respond more rapidly to dupilumab treatment in comparison to adolescents and adults. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 144(8) (pp S48-S48)
• Cork MJ, Leung DYM, Ong P, Danby SG, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Praestgaard A, Bologna G & Zhang A (2023) . Journal of Investigative Dermatology, Vol. 143(11) (pp S342-S342)
• Siegfried EC, Cork MJ, Boguniewicz M, Deleuran M, Simpson EL, Chen Z, Clearfield D, Shah P & Marco AR (2023) . British Journal of Dermatology, Vol. 188(Supplement_3)
• Paller AS, Eichenfield LF, Silverberg JI, Cork MJ, Bangert C, Irvine AD, Weidinger S, Barbarot S, Fan H, Alderfer J , Koppensteiner H et al (2023) . British Journal of Dermatology, Vol. 188(Supplement_3)
• Paller AS, Siegfried EC, Sidbury R, Lockshin B, Cork M, Pinter A, Xiao J, Khokhar FA, Bansal A & Prescilla R (2023) . British Journal of Dermatology, Vol. 188(Supplement_3)
• Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) . British Journal of Dermatology, Vol. 188(Supplement_3)
• Siegfried EC, Cork MJ, Arkwright PD, Wollenberg A, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL (2023) . British Journal of Dermatology, Vol. 188(Supplement_2)
• Pinter A, Cork MJ, Siegfried EC, Arkwright PD, Wollenberg A, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL (2023) Dupilumab Treatment is Not AssociatedWith an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 yearsWithModerate-to-Severe Atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 100-101)
• Paller A, Siegfried E, Sidbury R, Lockshin B, Cork M, Pinter A, Xiao J, Stanton S, Khokhar F, Bansal A & Prescilla R (2023) Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB100-AB100)
• Wollenberg A, Cork MJ, Flohr C, Bewley A, Blauvelt A, Hong-H C-H, Imafuku S, Schuttelaar M-LA, Simpson E, Soong W , Amoudruz P et al (2023) SAFETY OF TRALOKINUMAB IN PAEDIATRIC PATIENTS AGED 12-17 WITH MODERATE-TO-SEVERE AROPIC DERMATITIS: RESULTS FROM THE PHASE 3 ECZTRA 6 TRIAL. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 58-58)
• Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB221-AB221)
• Wollenberg A, Cork MJ, Hong HC-H, Taveira CM, Kurbasic A, Vacko E & Paller AS (2023) PROGRESSIVE AND SUSTAINED DISEASE CONTROL IN PATIENTS WITH ATOPIC DERMATITIS (AD) AGED 12-17 YEARS TREATED WITH TRALOKINUMAB FOR 52 WEEKS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 30-30)
• Simpson E, Paller A, Wollenberg A, Bewley A, Cork M, Hong C-H, Soong W, Almgren P, Carlsson A & Blauvelt A (2023) Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB190-AB190)
• Wollenberg A, Paller AS, Bewley A, Cork M, Hong C-H, Soong W, Oland CB, Taveira CM, Gjerum L & Blauvelt A (2023) LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
• Paller AS, Ramien M, Cork MJ, Simpson EL, Lee LW, Eichenfield LF, Coleman A, Gherardi G, Tian T, Zhang A & Cyr SL (2023) LONG-TERM DUPILUMAB TREATMENT IS NOT ASSOCIATED WITH AN INCREASED OVERALL RISK OF INFECTIONS IN PATIENTS AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN AN OPENLABEL EXTENSION STUDY. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
• Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Vass M, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB62-AB62)
• Paller A, Eichenfield LF, Cork MJ, Bangert C, Irvine AD, Weidinger S, Johnson S, Lazariciu I & Koppensteiner H (2023) Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 77-77)
• Cork MJ, Paller AS, Siegfried EC, Xiao J, Prescilla R, Dubost-Brama A & Bansal A (2023) EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 53-53)
• Cork MJ, Leung DYM, Ong P, Danby SG, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Praestgaard A, Bologna G & Zhang A (2023) Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 143(11) (pp S342-S342)
• Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Praestgaard A, Prescilla R, Wang Z & Marco AR (2023) Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB40-AB40)
• Weidinger S, Pinter A, Cork MJ, Arkwright PD, Simpson EL, Praestgaard A, Shumel B & Rodriguez Marco A (2023) Sequence of improvement in atopic dermatitis signs and symptoms in patients aged 6 months to 17 years treated with dupilumab. ALLERGY, Vol. 78 (pp 196-196)
• Leung DY, Cork MJ, Ong P, Danby S, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Bologna G & Zhang A (2023) Dupilumab treatment normalizes skin barrier function and symptoms in children aged 6-11 years with moderate-to-severe atopic dermatitis. ALLERGY, Vol. 78 (pp 194-194)
• Riechmann J, Ajtai SS & Cork MJ (2023) Allergy profile for patients receiving dupilumab for severe atopic dermatitis. ALLERGY, Vol. 78
• Cork MJ, Beck LA, Deleuran M, Hong HC-H, Adam DN, Hussain I, Zhang H, Shabbir A, Rodriguez Marco A & Levit NA (2022) Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1014-1014)
• Cork MJ, Wollenberg A, Siegfried E, Chen Z, Levit NA & Rodriguez Marco A (2022) Dupilumab treatment is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels in children aged 6 to 11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1059-1059)
• Cork MJ, Papp KA, Deleuran M, Pink AE, Reich K, Biswas P, Chan G, Feeney C, Chiu WS & Randall RM (2022) Long-term efficacy of abrocitinib after initial successful treatment in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 72-72)
• Flohr C, Jones A, Rosala-Hallas A, Beattie P, Baron S, Browne F, Brown S, Gach J, Hearn R, Esdaile B , Cork M et al (2022) A randomized controlled trial assessing the effectiveness and safety of ciclosporin vs. methotrexate in the treatment of severe atopic eczema in children and young people: the TREatment of severe Atopic eczema Trial (TREAT). BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 13-14)
• Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R , Lockshin B et al (2022) Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E173-E173)
• Paller AS, Cork MJ, Siegfried EC, Guttman-Yassky E, Simpson EL, Soong W, Xiao J, Wang Z, Chuang C-C, O'Malley JT & Bansal A (2022) Efficacy and safety of dupilumab in children aged 6-11 years with inadequately controlled severe atopic dermatitis: results from an open-label extension trial up to 1 year. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E159-E160)
• Paller A, Blauvelt A, Soong W, Imafuku S, Hong C-H, Schuttelaar MLA, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Cork M et al (2022) Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E90-E91)
• Simpson E, Blauvelt A, Silverberg JI, Cork M, Katoh N, Mark T, Schneider S & Wollenberg A (2022) Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 142(8) (pp B17-B17)
• Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Zhang H, Wang Z & Marco AR (2022) Dupilumab treatment improved sleep quality in moderate-to-severe atopic dermatitis in children aged 6 months-5 years and their caregivers. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E112-E113)
• Weidinger S, Cork M, Reich A, Beiber T, Gilbert S, Brennan N, Wilson R, Quaratino S & Porter-Brown B (2022) A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E96-E96)
• Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Zhang H, Wang Z & Rodriguez Marco A (2022) Dupilumab treatment improves health-related quality of life in children aged 6 months-5 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E104-E105)
• Paller AS, Cork MJ, Siegfried EC, Simpson EL, Wollenberg A, Gonzalez ME, Sun Y, O'Malley JT & Bansal A (2022) Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 12-12)
• Cork M, Beck L, Bissonnette R, Wollenberg A, Simpson E, Praestgaard A, Aamodt K & Rossi A (2022) Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 69-69)
• Cork MJ, Yosipovitch G, Silverberg JI, Praestgaard A, Zhang H, Wang Z & Rossi AB (2022) Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 79-79)
• Paller A, Blauvelt A, Soong W, Imafuku S, Hong C, Schuttelaar MLA, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Schneider S et al (2022) Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E145-E146)
• Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A, Ulhaq I, Fasth A, Carlander K, Holm T , Cork MJ et al (2022) EFFECTS OF EMOLLIENT CREAMS ON THE SKIN BARRIER OF PATIENTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 102 (pp 35-36)
• Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) (pp a68.2-a6a69)
• Cork MJ, Wollenberg A, Siegfried EC, Arkwright PD, Chen Z, Levit NA, Marco AR & Radwan A (2021) Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1659-1659)
• Paller A, Wollenberg A, Cork M, Siegfried E, Chen Z, Vakil J, Levit N, Marco AR & Radwan A (2021) Dupilumab treatment leads to mild transient increases in eosinophil levels without clinical relevance in children aged 6-11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1687-1688)
• Cork MJ, Lockshin B, Blauvelt A, Chen Z, Vakil J & Khokhar FA (2021) Fifty-two-week laboratory safety findings from an open-label extension study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E121-E121)
• Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Chen Z, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E115-E116)
• Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
• Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Chen Z, Delevry D, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
• Paller AS, Cork MJ, Marcoux D, Wollenberg A, Prescilla R, Chen Z, Rossi AB & Shumel B (2021) Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6-11 years with severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB136-AB136)
• Paller A, Cork MJ, Marcoux D, Zhang H, Chuang C, Zhang A & Chao J (2021) Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 141(5) (pp S84-S84)
• Wollenberg A, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Bansal A & Shumel B (2021) LABORATORY SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS AGED >= 6-< 12 YEARS WITH SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 3 TRIAL (LIBERTY AD PEDS). ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 59-59)
• Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Chen Z, Prescilla R, Delevry D, O'Malley JT & Bansal A (2021) LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN A PHASE 3 OPEN-LABEL EXTENSION TRIAL (LIBERTY AD PED-OLE) IN PATIENTS AGED >= 6 TO < 12 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 60-60)
• Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Bastian M, Chen Z, Delevry D, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 14-14)
• Lio P, Cork MJ, Blaiss MS, Kessel A, Cantrell WC, Werth JL, O'Connell M, Zang C & Takiya L (2021) Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E110-E110)
• Bewley A, Thyssen JP, Chiu WS, Rojo R, Biswas P, Feeney C, DiBonaventura M, Misery L, Stander S & Cork M (2021) Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E72-E73)
• Paller AS, Weidinger S, Cork MJ, Marcoux D, Katoh N, Zhang H, Rossi AB, Shumel B, Zhang A, Prescilla R & Chao J (2021) Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB141-AB141)
• Lio PA, Spergel JM, Cork MJ, Blaiss MS, Kessel A, Cantrell WC, Werth JL, O'Connell MA, Zang C & Takiya L (2021) Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB97-AB97)
• Simon JC, Barbarot S, Gooderham M, Simpson E, Kurbasic A, Olsen CK, Cork MJ & Silverberg JI (2021) The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 56-56)
• Silverberg JI, Barbarot S, Gooderham M, Simon JC, Simpson E, Kurbasic A, Olsen CK & Cork MJ (2021) Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E65)
• Silverberg JI, Cork M, Wollenberg A, Katoh N, Steffensen LA, Kurbasic A, Olsen CK, Kuznetsova A, Osterdal ML, Vilsboll AW , Deleuran M et al (2021) Early changes in patient-relevant endpoints in three tralokinumab pivotal phase III trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E64)
• Danby SG, Andrew PV, Pinnock A, Kay L, Chittock J & Cork MJ (2021) LOWERING SKIN SURFACE PH WITH A TOPICAL ZINC LACTOBIONATE PREPARATION CONTAINING PHYSIOLOGIC LIPIDS IMPROVES SKIN BARRIER STRUCTURE AND FUNCTION IN ADULTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 51-51)
• Wollenberg A, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, Vakil J & Khokhar FA (2021) Laboratory safety of dupilumab in paediatric patients aged >= 6 to < 12 years with severe atopic dermatitis: results from a phase III trial (LIBERTY AD PEDS). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E122-E123)
• Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ , Sach TH et al (2021) A RANDOMISED CONTROLLED TRIAL OF DAILY EMOLLIENT DURING INFANCY FOR PREVENTING ECZEMA - RESULTS OF THE BEEP TRIAL. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 7-8)
• Danby SG, Andrew P, Kay L, Pinnock A, Chittock J, Brown K & Cork MJ (2020) An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB71-AB71)
• Cork MJ, Lockshin B, Morren M-A, Etoh T, Chen Z, Rossi AB, Lu Y, Bansal A & Shabbir A (2020) Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB39-AB39)
• Flohr C, Beattie P, Cork M, Brown S, Burton T, Gholam K, Griffiths C, Ingram J, Irvine A, Langan S , Manca A et al (2020) The use of systemic immunomodulatory agents in the treatment of children and adolescents with atopic eczema: lessons from the UK-Irish Atopic Eczema Systemic Therapy (A-STAR) Register. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-148)
• Shabbir A, Paller AS, Lockshin B, Cork MJ, Morren M, Kataoka Y, Chen Z, Rossi AB & Lu Y (2020) Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 140(7) (pp S60-S60)
• Simpson EL, Sinclair R, Forman S, Wollenberg A, Asch R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Magnolo N , Maari C et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183(4) (pp E105-E106)
• McPherson T, Cork M, Michaelis L, Flohr C, Davis L, Petrovic M, Hennessy L, Rajkovic I & Hudson R (2020) A real-world observational study to describe National Health Service resource use for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents aged 6-17 years. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-147)
• Cork MJ, Eichenfield LF, Blauvelt A, Rosmarin D, Hussain I, Davis JD, Li M, Zhang Q, Gadkari A, Eckert L , Kamal MA et al (2019) . Journal of Investigative Dermatology, Vol. 139(5) (pp s104-s104), 8 May 2019 - 11 May 2019.
• Cork MJ, Eichenfield LF, Blauvelt A, Rosmarin D, Hussain I, Davis JD, Li M, Zhang Q, Gadkari A, Eckert L , Kamal MA et al (2019) Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 139(5) (pp S104-S104)
• de Bruin-Weller M, Eckert L, Simpson EL, Cork MJ, Ardeleanu M, Chen Z, Shumel B, Rossi AB, Graham NMH, Pirozzi G & Gadkari A (2019) Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 17 (pp 116-116)
• Chittock J, Brown K, Cork MJ & Danby SG (2018) Quantification of natural moisturizing factors at the skin surface using a portable infrared spectrometer device: a pilot, calibration model. BRITISH JOURNAL OF DERMATOLOGY, Vol. 179(1) (pp E35-E36)
• Cork MJ, Thaci D, Davis JD, Zhang Q, Akinlade B, Graham NMH, Pirozzi G & Bansal A (2017) An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 155-155)
• Cork MJ, Thaci D, Davis JD, Zhang Q, Akinlade B, Graham NMH, Pirozzi G & Bansal A (2017) An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 67-68)
• Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour J-P , Kingo K et al (2017) Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 15 (pp 79-79)
• Byers RA, Maiti R, Danby SG, Pang EJ, Mitchell B, Carr¨¦ MJ, Lewis R, Cork MJ & Matcher SJ (2017) . Proceedings of SPIE, Vol. 10037
• De Bruin-Weller M, Gadkari A, Simpson E, Cork M, Puig L, Girolomoni G, Wollenberg A, Chen Z, Radin A, Shumel B , Ardeleanu M et al (2017) DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN ATOPIC DERMATITIS PATIENTS INADEQUATELY CONTROLLED, INTOLERANT, OR INADVISABLE FOR CYCLOSPORINE-A. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, Vol. 119(5) (pp S94-S95)
• Danby S, Wan H, Chittock J, Brown K, Wigley A & Cork M (2016) Characterisation of the skin barrier defect in atopic dermatitis using in vivo ATR-FTIR spectroscopy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 136(9) (pp S182-S182)
• Cooke A, Cork M, Victor S, Campbell M, Danby S, Chittock J & Lavender T (2015) A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 173 (pp 153-153)
• Danby S, Brown K, Higgs-Bayliss T, Chittock J & Cork M (2014) The effect of a complex emollient cream containing 5% urea, ceramide 3 and lactic acid, compared with a simple emollient, on the skin barrier in older people with dry skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 171 (pp 57-58)
• Chalmers JR, Simpson EL, Chen YY, Cork MJ, Brown SJ, Thomas KS, Williams HC & Grp BEEPS (2014) Feasibility study of Barrier Enhancement For Eczema Prevention (BEEP). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E8-E9)
• Higgs-Bayliss T, Brown K, Chittock J, Cork MJ & Danby SG (2014) Noninvasive assessment of the lipid structure and water holding properties of the stratum corneum in vivo by ATR-FTIR using a fibre optic probe in patients with atopic dermatitis and healthy controls. BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E29-E29)
• Chalmers JR, Thomas KS, Montgomery A, Sach T, Boyle RJ, Ridd MJ, Simpson EL, Cork MJ, Brown SJ, Lawton S , Thornton J et al (2014) A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E32-E32)
• Shareef MS, Albenali L, Cork MJ & Clark SM (2013) A difficult case of atopic eczema: useful learning points. BRITISH JOURNAL OF DERMATOLOGY, Vol. 169 (pp 120-120)
• Danby S, Chittock J, Martin KM, Cork MJ & Tierney NK (2013) Chymotrypsin-like protease activity in the stratum corneum is increased in atopic dermatitis and upon washing with soap. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 68(4) (pp AB172-AB172)
• Cork MJ (2012) Skin barrier breakdown in atopic dermatitis: the effect of topical products. INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Vol. 34(4) (pp 363-364)
• Albenali L, Danby S, Moustafa M, Chittock J, Kennedy K, Shackley F & Cork MJ (2012) Vitamin D supplementation improves atopic dermatitis and atopic dermatitis complicated by eczema herpeticum. BRITISH JOURNAL OF DERMATOLOGY, Vol. 167 (pp 127-127)
• Danby S, Al Enezi T, Chittock J, Kennedy K, Sultan A & Cork M (2011) A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 115-115)
• Danby S, Al Enezi T, Chittock J, Kennedy K, Sultan A & Cork M (2011) A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 44-45)
• Moustafa M, Holden C, Athavale P, Cork M, Messenger A & Gawkrodger DJ (2009) Patch testing is a useful investigation in children with eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 125-125)
• Al Enezi T, Sultan A, Chittock J, Moustafa M, Danby S & Cork MJ (2009) . BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 115-116)
• Danby S, Moustafa M, MacGowan AL, Ward SJ & Cork MJ (2009) Skin protease inhibitors: a new treatment for atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 30-31)
• Danby S, Moustafa M, MacGowan AL, Ward SJ & Cork MJ (2009) Skin protease inhibitors: A new treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 60(3) (pp AB67-AB67)
• Carr J, Akram M, Sultan A, Hunter L, Moustafa M, Messenger AG, Fenton P & Cork MJ (2008) Contamination of emollient creams and ointments with Staphylococcus aureus in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 114-114)
• Harcastle NJ, MacGowan AL, Henderson JK, Cork MJ & Ward SJ (2008) Vitamin A metabolic pathway inhibition: a new therapeutic approach to treating psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 118-118)
• Cork MJ, Varghese J, Hadcraft J, Lane M, Ferguson A, Moustafa M, Guy RH & Ward S (2007) Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - Implications for therapy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 127 (pp S45-S45)
• Kemp EH, McDonagh AJG, Wengraf DA, Messenger AG, Gawkodger DJ, Cork MJ & Tazi-Ahnini R (2007) Severe alopecia areata is associated with a functional polymorphism in the PTPN22 gene. IMMUNOLOGY, Vol. 120 (pp 70-70)
• Cork M, Robinson D, Vasilopoulos Y & Ferguson A (2007) The effects of topical corticosteroids and pimecrolimus skin barrier function, gene expression, and topical drug penetration in atopic eczema and unaffected controls. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 56(2) (pp AB69-AB69)
• Simon M, Tazi-Ahnini R, Jonca N, Cork MJ & Serre G (2006) Reduced and abnormal proteolysis of corneodesmosomal proteins in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 126 (pp 116-116)
• Lovewell TRJ, Cork MJ, Wengraf DA, Messenger AG, McDonagh AJG & Tazi-Ahnini R (2006) A study on the effect of genetic variants of the autoimmune regulator (AIRE) promoter, on AIRE activity and downstream Aire-regulated genes. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 250-250)
• Vasilopoulos Y, Cork MJ, Sagoo GS, Ward SJ, Duff GW & Tazi-Ahnini R (2006) A synonymous single nucleotide polymorphism in human cystatin A, a candidate gene in the PSORS5 locus, confers susceptibility to psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 235-235)
• Cork M, Robinson D, Vasilopoulos Y & Ferguson A (2006) Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 54(3) (pp AB3-AB3)
• Cork MJ, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, Tazi-Ahnini R & Ward SJ (2005) Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 605-605)
• Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, Tazi-Ahnini R & Ward SJ (2005) Treatment of atopic dermatitis from a skin barrier perspective. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 611-611)
• Cork M (2005) Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 52(3) (pp P9-P9)
• Cork MJ, Timmins J, Holden C, Carr J, Berry V, Tazi-Ahnini R & Ward SJ (2004) An audit of adverse drug reactions to aqueous cream in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 151 (pp 57-58)
• Simon M, Tazi-Ahnini R, Cork MJ & Serre G (2003) Abnormal proteolysis of corneodesmosin in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 121(6) (pp 1568-1568)
• Tazi-Ahnini R, Vasilopoulos Y, Henderson JK, Murphy R, Williams H, Ward SJ, Duff GW & Cork MJ (2003) Role of variants within genes regulating the skin barrier in the pathogenesis of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 149 (pp 4-4)
• Wengraf DA, McDonagh AJG, Cork MJ, Gawkrodger D, Messenger AG & Tazi-Ahnini R (2003) Genetic analysis of the autoimmune regulator (aire) gene: potential role of aire in susceptibility to alopecia universalis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 849-850)
• McDonagh AJG, Messenger AG, Birch MP, Cork MJ & Tazi-Ahnini R (2003) Alopecia areata: age at onset, atopy & disease associations. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 866-867)
• Price VH, Stenn KS, Duvic M, Goldsmith LA, Cork MJ, Happle R, Kalabokes V & Moshell AN (1999) . Journal of Investigative Dermatology Symposium Proceedings, Vol. 4(3) (pp 199-199)
• CORK M (1996) . Journal of the European Academy of Dermatology and Venereology, Vol. 7 (pp S31-S37)
• Paller A, Blauvelt A, Soong W, Imafuku S, Hong C-H, Schuttelaar M, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Cork M et al () . SKIN The Journal of Cutaneous Medicine, Vol. 6(2) (pp s29-s29)

Reports

• Danby SG, Ewence A, Rumsby P, Cork MJ, Williams HC, Rockett L & Davey HMSAUIII-PP (2011) A systematic review of skin irritation and tap water

Posters

• Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) 41343 Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis.
• Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Praestgaard A, Prescilla R, Wang Z & Rodriguez Marco A (2023) 41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers.
• Simpson E, Paller A, Wollenberg A, Bewley A, Cork M, Hong C-H, Soong W & Almgren P (2023) 43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND.
• Paller A, Siegfried E, Sidbury R, Cork M, Pinter A, Xiao J, Stanton S, Khokhar F, Bansal A & Prescilla R (2023) 42924 Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial.
• Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Vass M, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis.
• Katibi OS, Andrew P, Poyner A, Pinnock A, Brown K, Byers R, Cork M & Danby S (2023) P24 Emollient use and effects on cutaneous allergen reactions: a preliminary study.
• Cork M, Bissonnette R, Ramirez-Gama M, Taylor P, Praestgaard A, Levit N, Rossi A & Zhang A (2023) P40 Dupilumab treatment restores skin barrier function in lesional and nonlesional skin of patients with atopic dermatitis and improves patient-reported outcomes.
• Paller AS, Cork MJ, Wollenberg A, Siegfried EC, Gonzalez ME, Lockshin B, Khokhar FA, Chen Z, Gonzalez T, Simcox E & Prescilla R (2023) P73 Laboratory safety from a 16-week phase III study of dupilumab in patients aged 6?months¨C5?years with moderate-to-severe atopic dermatitis.
• Paller AS, Cork MJ, Flohr C, Bangert C, Weidinger S, Nesnas J, Farooqui SA, Biswas P, Watkins M & Koppensteiner H (2023) P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND.
• Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) 392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis.
• Weidinger S, Cork M, Reich A, Bieber T, Lucchesi D, Rynkiewicz N, Sainson RCA, Chen R, Prandi F, van?Krinks C , Stebegg M et al (2023) 353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay.
• Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Brennan N, Wilson R, Lucchesi D, Rynkiewicz N, Stebegg M & Porter-Brown B (2023) 345 Treatment with amlitelimab¡ªa novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody¡ªreduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis.
• Ong P, Cork MJ & Armstrong A (2022) 34326 Real-world analysis of skin infections and antimicrobial use among patients with atopic dermatitis before and after initiation of dupilumab treatment.
• Weidinger S, Bieber T & Cork M (2022) 34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis.
• Winder N & Cork M (2022) 33569 Optimization of common hand cleansers for protection from viral spread and occupational hand dermatoses.
• Paller A, Eichenfield LF & Cork MJ (2022) 34655 Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program.
• Weidinger S, Bieber T, Cork M, Reich A, Brennan N, Quaratino S, Wilson R & Porter-Brown B (2022) 33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD).
• Simpson E, Blauvelt A, Silverberg JI, Cork M, Katoh N, Mark T, Schneider S & Wollenberg A (2022) LB946 Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment.
• Paller AS, Weidinger S, Cork MJ, Marcoux D, Katoh N, Zhang H, Rossi AB, Shumel B, Zhang A, Prescilla R & Chao J (2021) 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial.
• Paller AS, Cork MJ, Marcoux D, Wollenberg A, Prescilla R, Chen Z, Rossi AB & Shumel B (2021) 27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6¨C11 years with severe atopic dermatitis (AD).
• Cork MJ, Tha?i D, Eichenfield L, Arkwright PD, Chen Z, Delevry D, O¡¯Malley JT & Bansal A (2021) 26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ¡Ý6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD).
• Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE).